Combination therapies for drug-resistant cancers
Monday, October 10, 2011 - 13:31
in Health & Medicine
Some cancers can be effectively treated with drugs inhibiting proteins known as receptor tyrosine kinases, but not those cancers caused by mutations in the KRAS gene. However, researchers have now identified a potential way to effectively use receptor tyrosine kinases inhibitors to treat individuals with KRAS mutant colorectal cancers -- combine them with inhibitors of the MEK/ERK signaling pathway.